Valor202020212022202320242025TTMGastos comerciales, generales y administrativos303.3 M348.4 M340.3 M368.4 M308 M186.1 M186.1 MInvestigación y desarrollo234.5 M234 M193 M111.4 M70.7 M53.2 M53.2 MBeneficio operativo433.8 M352.6 M172.7 M726.4 M108.7 M100.1 M100.1 MTotal de ingresos no operativos26.6 M38.2 M49 M4.8 M34.2 M17.3 M17.3 MGastos por intereses, netos de intereses capitalizados31.3 M34.5 M37.3 M87.9 M71 M59.3 M59.3 MIngresos no operativos, una vez deducidos los gastos por intereses-9.4 M00-92 M-49.3 M-96.2 M-96.2 MIngresos/gastos extraordinarios4.7 M3.7 M11.7 M8.9 M12.5 M54.2 M54.2 MBeneficio antes de impuestos407.2 M314.4 M221.7 M731.2 M142.9 M82.8 M82.8 MParticipación en los beneficios———————Impuestos102.1 M83.5 M2.1 M29.3 M47.7 M30.2 M30.2 MParticipación minoritaria———————Otros ingresos/gastos después de impuestos5.2 M2 M6.4 M13 M6.5 M400 K400 KBeneficio neto antes de actividades interrumpidas305.1 M230.9 M223.8 M760.5 M190.6 M52.6 M28.6 MOperaciones suspendidas———————Beneficio neto305.1 M230.9 M223.8 M760.5 M190.6 M52.6 M28.6 MAjuste por dilución———————Dividendos de las acciones preferentes———————Beneficio neto diluido atribuible a los accionistas305.1 M230.9 M223.8 M760.5 M190.6 M52.6 M28.6 MBeneficio básico por acción5.794.32-4.47-14.85-3.60.980.98Beneficio por acción diluido5.674.27-4.47-14.85-3.60.930.93Número medio de acciones ordinarias52.7 M53.5 M50.1 M51.2 M53 M53.5 M216.1 MAcciones diluidas53.8 M54.1 M50.1 M51.2 M53 M56.7 M227.4 MEBITDA-343.4 M258.4 M-910.4 M-1.6 B-341.9 M-320.9 M-320.9 MEBIT-393.5 M4.2 M-1.21 B-1.73 B-393.3 M-407.7 M-407.7 MCosto de los ingresos524 M—693.7 M705.4 M—326.2 M326.2 MOtros costes de producción———————Amortización y depreciación (flujo de caja)50.1 M254.2 M296.3 M125.1 M108.8 M95.8 M95.8 M
Emergent BioSolutions Inc
Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. It develops vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and it provides medical devices for biodefense purposes.
Among the company's products are the controversial BioThrax, the only anthrax vaccine licensed by the U.S. Food and Drug Administration and Narcan for the emergency treatment of opioid overdose. The company also manufactures pharmaceuticals for infectious diseases like cholera and typhoid.
During the COVID-19 pandemic, Emergent BioSolutions also produced Johnson & Johnson/Janssen and Oxford–AstraZeneca vaccines at one of its plants; however, this was marked by contamination and other production issues, and millions of doses of vaccine had to be discarded.